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Hepatocellular carcinoma (HCC) is the 5th most common tumour worldwide and has a dark prognosis. For nonoperable cases,
metabolic radiotherapy with Lipiodol labelled with β-emitters is a promising therapeutic option. The Comprehensive Cancer
Centre Eug` ene Marquis and the National Graduate School of Chemistry of Rennes (ENSCR) have jointly developed a stable and
eﬃcient labelling of Lipiodol with rhenium-188 (Eβmax = 2.1MeV) for the treatment of HCC. The major “milestones” of this
development, from the ﬁrst syntheses to the recent ﬁrst injection in man, are described.
1.Introduction
Hepatocellular carcinoma (HCC) is the ﬁfth most common
tumour worldwide and even ranks second in terms of
mortality [1, 2]. Moreover, only a small number of cases are
eligible to curative treatments, such as resection or trans-
plantation. For the rest, a wide range of palliative treatments
can be proposed, among which are chemoembolisation and
radioembolisation with Lipiodol [3–6]. Lipiodol is an oily
medium which has shown to be selectively retained in
tumour when administered intra-arterially [7]. Lipiodol has
been labelled with iodine-131 [8, 9], rhenium-188 [10, 11],
yttrium-90 [12, 13], holmium-166 [14], and lutetium-177
[15]. Some early trials with phosphorus-32 have also been
described [16]. However, to date, only the ﬁrst two have been
used in man, the iodine-131-labelled Lipiodol (Lipiocis)
having a market authorisation. 188Relabelled Lipiodol seems
the most promising one, being able to circumvent the
major drawbacks of iodine-131 (long half-life, medium beta
energy, strong gamma energy, and cost). Indeed, rhenium-
188 has ideal properties for molecular radiotherapy (Eβmax =
2.1MeV with a maximum tissue penetration of 11mm, Eγ =
155keV (15%), t1/2 = 17h) and has the added advantage of
being available on a cost-eﬀective day-to-day basis thanks to
its generator mode of production [17]. It has thus attracted
much interest [18, 19].
First attempts to label Lipiodol with radioisotopes other
than iodine-131 were done with a covalently bond chelate,
with disappointing results [12, 20]. It was thus postulated
that solubilisation of a lipophilic chelate into Lipiodol
would make a suitable “radiolabelling” [21]. Soon after,
several teams investigated this promising approach [22,
23]. It is in that context that the Centre Eug` ene Marquis
and the Ecole Nationale Sup´ erieure de Chimie de Rennes
(ENSCR) decided to combine respectively their experience
on radioembolisation of HCC with 131I-Lipiodol [9, 24–27]
and knowledge of technetium and rhenium coordination
chemistry [28–31], to label Lipiodol with a 188Rechelate of
their own design.
2.Synthesis
2.1. 185/187Re/99Tc Syntheses. Previous studies at the ENSCR
led to the preparation of a new class of complexes with
perthiobenzoate and dithiobenzoate moieties [M (PhCS3)2
(PhCS2)] which structure is given in Figure 1,b o t hw i t h
rhenium[32]andwithtechnetium-99[33].Thesecomplexes
were nicknamed SSS, standing for “Super-Six sulphur”,2 International Journal of Molecular Imaging
Figure 1: Superposition of the crystal structures of 185/187Re-SSS
and 99Tc-SSS complexes (reprinted from: N. Lepareur, Ph.D. thesis
no. 2003 REN 10110, 2003).
Reducing kit (gluconate/SnCl2)
NaTcVIIO4 Na[TcVO(gluc)2]
Na[TcVO(gluc)2]
PhCS2Na (2 mg)
Saline, RT, 10 min
Saline, 100◦C, 30 min
[TcIII(PhCS3)2(PhCS2)]
Figure 2: Synthesis of 99mTc-SSS.
because the metal core is coordinated by six sulphur atoms.
One of the interests of these complexes is that the metal is at
the oxidation state +III, which is more stable than +V and
they are, in addition, susceptible to bifunctional approach to
design target-speciﬁc agents [31, 34].
2.2. 99mTc Synthesis. The SSS complex was subsequently
prepared with technetium-99m, using a freeze-dried kit
method (containing 0.75mg tin chloride, 75mg calcium
gluconate,and25mgsodiumchloride,diluted1/10),initially
in a view of lymphocytes labelling [35]. The complex
was obtained, according to procedure shown in Figure 2,
with good yield and good radiochemical purity (>95%).
Moreover, it proved to be very stable and to be quite
lipophilic (logP = 3.33).
It was, therefore, a good candidate to label Lipiodol.
The method previously described by Jeong et al. [22]w a s
used, that is, once the complex is synthesised, 2-3mL of
Lipiodol Ultra-Fluide (simply called Lipiodol) is added. The
mixture is shaken then centrifuged at 2200g for 10min, and
the phases are carefully collected. 99mTc-SSS/Lipiodol is thus
obtainedwitha96±2.8%yieldandaﬁnalRCPof92.5±2.6%
[36]. The preparation showed satisfactory reproducibility,
and the labelling proved to be stable.
2.3. 188Re Synthesis. Rhenium-188 is obtained in the form
of perrhenate by elution of a 188W/188Re generator, similar
to the 99Mo/99mTc generator. The major diﬀerence lies in
Concentration
Concentration kit
module
Generator 188ReO−
4
Figure 3: 188W/188Re generator and its remote-controlled elu-
tion/concentration system (IRE, Fleurus, Belgium).
Figure 4: TADDEO module (COMECER, Castel Bolognese, Italy).
the necessity of postelution concentration to obtain high-
volumicactivity(upto20GBq/mLwitha37GBqgenerator),
due to the lower speciﬁc activity of 188Wc o m p a r e dt o
99Mo, necessitating a bigger alumina column (see Figure 3).
First trials to prepare 188Re-SSS proved to be disappointing.
Indeed, rhenium-188, though its chemistry is very close
to that of technetium-99m, is much harder to reduce and
tends to reoxidise very quickly. It requires harsher reaction
conditions. As a consequence, reaction conditions as well
as kit composition had to be modiﬁed [37]. Amounts and
type of reducing agent were varied as well as ancillary ligand.
Antioxidants and chelating agents were added. Volume, pH,
heatingtemperature,andreactiontimewerealsomodulated.
Eventually, the solution came with the adjunction of potas-
sium oxalate, which eases the reduction of perrhenate byInternational Journal of Molecular Imaging 3
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Figure 5: Flowchart of the TADDEO module for the preparation of 188Re-SSS/Lipiodol.
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Figure 6: Mean dose equivalents (mSv/GBq) for both hands for
manual (n = 3) and automated (n = 2) preparations of 188Re-
SSS/Lipiodol, measured with TLD ﬁxed at the tips of the indexes.
expanding its coordination sphere, as shown by Boschi et al.
[38]. Finally, the optimal procedure was determined as
Kit formulation: 0.8mg SnCl2·2H2O (dissolved in
0 . 1m LH C l1M ) ,7 . 5m gs o d i u mg l u c o n a t e ,3 0m ga s c o r b i c
acid, and 40mg potassium oxalate. This freeze-dried kit is
reconstituted in 0.5mL saline, and the perrhenate (0.5mL
of saline) is then added. After 15min at room temperature,
20mg of sodium dithiobenzoate is added, and the solution
is heated for 30min at 100◦C, to provide the 188Re-SSS
complex, as a precipitate. 2-3mL of Lipiodol is added to the
mixture, which is then centrifuged, as previously described
withtechnetium-99m.188Re-SSS/Lipiodolwasobtainedwith
a8 7±9.1% yield and a ﬁnal RCP of 93±3.4%. Labelling was
further optimised to reach 97.3 ±2.1% yield and a ﬁnal RCP
of 94.1 ±1.7% [39].
Ex vivo biodistribution 99mTc-SSS/lipiodol
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Figure 7: Ex vivo biodistribution of 99mTc-SSS/Lipiodol in healthy
pigs (n = 2 for each time point).
2.4. High-Activity Upgrade and Automation. An e we ﬃcient
and stable labelling of Lipiodol was described. However,
for activities above 1850MBq (therapeutic activities), the
labellingyielddecreaseddramatically.Consequently,thesyn-
thesishadtobefurtherimproved,inviewofHCCtreatment.
Kit formulation was tuned, and reaction conditions were
slightly modiﬁed.
A freeze-dried kit (4mg SnCl2·2H2O (dissolved in
0.1mL HCl 1M), 30mg sodium gluconate, 30mg ascorbic
acid, 40mg potassium oxalate) is reconstituted in 0.5mL
saline, and the perrhenate (0.5mL of saline) is then
added. After 15min at room temperature, 40mg of sodium
dithiobenzoate is added, and the solution is heated for
15min at 100◦C, to provide the 188Re-SSS complex, as a
precipitate. 2-3mL of Lipiodol is added to the mixture,4 International Journal of Molecular Imaging
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Figure 8: Scintigraphic scans of 188Re-SSS/Lipiodol 48h after intra-arterial injection in healthy pigs.
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Figure 9: Ex vivo biodistribution of 188Re-SSS/Lipiodol in healthy
pigs (n = 2 for each time point).
which is then stirred with a vortex. After 10min of centrifu-
gation (2200g), both phases are separated, and the lower
phase (radiolabelled Lipiodol) is carefully recovered. 188Re-
SSS/Lipiodol is obtained with a 98.56 ± 1.2% yield and a
ﬁnal RCP of 92.52 ± 2.3% and is stable for at least 7 days
[40].
Having to handle high activities of 188Re to prepare ther-
apeutic doses can result in an excessive radiation exposure
to the operator, and particularly at the ﬁnger tips [41].
The authors have thus developed an automated procedure
to limit the radiation exposure to the personnel, as well
as to have a reproducible synthesis, in view of clinical
trials [40]. The remote-controlled system employed is a
TADDEO module (COMECER, Castel Bolognese, Italy) and
is displayed in Figure 4. The radiolabelling procedure was
once more adapted to be automated. The main change was
the substitution of the centrifugation step and the use of
solid-phase extraction cartridges to purify the product. The
ﬁ n a ly i e l di ss o m e w h a tl o w e rt h a nw i t hm a n u a lp r e p a r a t i o n
(52.68 ± 9.6%), due to the loss of activity in the tubing and
the vessels (Figure 5).
The foremost gain of the automation was in the dose
received by the operator. This is particularly true for the
dose to the extremities. Impact of the automation was
studied with thermoluminescent dosimeters (TLD) ﬁxed
at the ﬁnger tips, and, respectively, 80 and 58% decreases
in the right-hand and left-hand doses were shown [42].
Personal dose equivalents—measured with continuously
readable EPD dosimeters—were reduced by 38 and 43% for
Hp (10) and Hp (0.07), respectively. Mean dose equivalents
(mSv/GBq) for both hands are displayed in Figure 6.
3.PreclinicalStudies
Good targeting and stability of radiolabelled Lipiodol were
investigated in vivo, in healthy pigs, then in hepatoma-
bearing rats. The radiotracer was injected through the hep-
atic artery, and biodistribution was checked by scintigraphy
and ex vivo countings. Autoradiography was also done, to
assess more precisely the ﬁxation of the radiotracer.International Journal of Molecular Imaging 5
Figure 10:Fusedautoradiography/histologytissuestainoftheliver,
1h after intra-arterial injection of 30MBq of 188Re-SSS/Lipiodol.
Radioactivity (black spots) is weakly noticeable in the region of
hepatic artery and portal space (big yellow arrow) and strongly in
capillary sinusoids (small yellow arrow), May Grumwald Giemsa
coloration, ×40.
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Figure 11: Ex vivo biodistribution of 188Re-SSS/Lipiodol in
hepatoma-bearing rats (n = 3 for each time point).
3.1. Healthy Pigs. 99mTc-SSS/Lipiodol could be useful for
carrying pretherapeutic dosimetry studies, as is performed
with 99mTc-MAA for 90Y-labelled microspheres [43]. It was
injected into the hepatic artery of healthy pigs and showed
a biodistribution pattern similar to that of 131I-labelled
Lipiodol in human [36]. It has a preferential liver uptake, as
shown in Figure 7. Fixation was stable and showed only mild
digestive elimination 24h after injection.
188Re-SSS/Lipiodol was also investigated in healthy pigs
[44]. Scintigraphic scans (Figure 8)a n dex vivo countings
(Figure 9) show the quasiexclusive hepatic ﬁxation, with
a slight pulmonary uptake (not visible on scintigraphy).
The ﬁxation also proved to be stable with a very weak
D0 D7 D14 D21 D28 D35 D42 D49 D56
B
o
d
y
 
t
e
m
p
e
r
a
t
u
r
e
 
(
◦
C
)
37
37.5
38
38.5
39
39.5
40
Re-SSS/lipiodol
Control group
(a)
0
2
4
6
8
10
12
B
o
d
y
 
w
e
i
g
h
t
 
(
k
g
)
D0 D7 D14 D21 D28 D35 D42 D49 D56
Re-SSS/lipiodol
Control group
(b)
Figure 12: Physiological parameters; toxicity study in dogs (n = 4
for each group).
urinary and intestinal elimination. At the microscopic level,
the radioactivity is mainly—and rapidly—located in the
sinusoids (Figure 10), as Lipiodol alone [45], where it is
retained.
3.2. HCC-Bearing Rats. Unfortunately, no porcine model of
hepatocarcinoma was described, and attempts to develop
onewithhumanhepatocarcinomacellsinimmunodepressed
pigs with cyclosporine gave no results. On the contrary,
murine hepatoma models are well documented. It was6 International Journal of Molecular Imaging
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Figure 13: Some clinical chemistry values; toxicity study in dogs (n = 4 for each group); ALT (alanine transaminase), AST (aspartate
transaminase), and bilirubin are biomarkers of liver function; creatinin is a marker of renal function.
thus decided to investigate the tumour uptake of 188Re-
SSS/Lipiodol in rats inoculated with N1S1 hepatocarcinoma
cell line [39]. Our team, in collaboration with J. P. Benoit’s
team in Angers, developed a new technique for the tumoral
inoculation as well as the intra-arterial injection [46].
Results showed preferential hepatic uptake, with a weak
to moderate pulmonary uptake, and, most importantly a
good tumour retention (Figure 11). This is consistent with
the other 188Relabelled Lipiodol methods. The tumour-to-
liverratioincreasesfrom2.9±1.5to4.1±0.7between1hand
48h. However, this model has its limitations, notably the fact
that a single small tumour in a rat is probably too small for
rhenium-188 to be truly eﬀective. Indeed, whencompared to
131I-lipiodol, the latter proved to be more eﬀective [47].
3.3. Toxicology Studies. To assess the safety of the radiotracer,
atoxicitystudy—acuteandchronic—hasbeenundertakenin
dogs (Beagles), with the nonradioactive analogue 185/187Re-
SSS/Lipiodol, prepared in the same conditions as for clinical
preparation (sterile GMP kits, same amounts of reactants,
remote-controlled procedure). The Re-SSS/Lipiodol was
injected for less than 24h after preparation.
The study comprised two phases. For the ﬁrst phase
(7 days), animals (3 males + 3 females) received a singleInternational Journal of Molecular Imaging 7
(a)
(b)
(c)
Figure 14: Scintigraphy (a) showing intense hyperﬁxation (in black) in 4 tumour foci, CT scan (b) showing intense Lipiodol retention
(in white) in the nodules and fusion image (c) of scintigraphy and CT scan; 71-year-old male, 1h after injection of 1.85GBq of 188Re-
SSS/Lipiodol. Transverse, sagittal, and coronal views.
injection at D1, and for the second one, animals (2 males +
2 females) received one dose at D1 and one at D30. Control
group (5 males + 5 females) received Lipiodol alone. Some
results are summarised in Figures 12 and 13. No change
related to the parenchyma of organs or at the site of injection
h a sb e e nd e t e c t e d ,e i t h e ra tD 7o ra tD 5 9 .
This study thus demonstrated lack of toxicity of Re-
SSS/Lipiodol, opening the way for the injection in human.
4.ClinicalInvestigation
Files were submitted to the relevant authorities, that is,
French Agency for the Safety of Health Products (AFSSAPS),
French Nuclear Safety Authority (ASN), and Ethical
Committee (Comit´ ed eP r o t e c t i o nd e sP e r s o n n e s , CPP),
and approval was eventually granted. A phase 1 escalation
dose study was thus initiated (Lip-Re-1, EudraCT no.
2009-013231-37). This study will comprise 4 dose stages,
ranging from 1.85 to 7.4GBq. Each stage will comprise 3 to
6 patients, depending on the toxicity (or lack thereof) of the
compound. To date, 5 patients have been injected (3 with
1.85GBq and 2 with 3.7GBq). For illustration, SPECT/CT
scans of the third patient 1h after injection of 1.85GBq
of 188Re-SSS/Lipiodol are shown in Figure 14, displaying
the good targeting of the radiopharmaceutical candidate
(tumour-to-nontumour max ratio = 15). 4 nodules are
clearly visible on the sagittal plane. This patient (71-year-old
male, with multifocal HCC, in progression after Sorafenib
treatment) responded well to the treatment, and his disease
was stabilised for a couple of months.
5. Conclusion
In conclusion, we have developed a potential HCC treatment
by radioembolisation, with a phase 1 clinical trial currently
in progress. This represents almost ten years of multidisci-
plinary research, from basic chemistry to clinic. Its clinical
relevance has now to be demonstrated, and its eﬃciency and
tolerance have to be compared to other existing therapeutic
options.
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